Want to see IN:WANBURY full AI Analyst Report?
WANBURY Stock Chart & Stats
₹332.50
-₹2.65(-0.80%)
At close: 4:00 PM EDT
₹332.50
-₹2.65(-0.80%)
Day’s Range― - ―
52-Week Range₹162.00 - ₹360.00
Previous CloseN/A
Volume188.34K
Average Volume (3M)8.26K
Market Cap
₹10.27B
Enterprise Value₹11.53B
Total Cash (Recent Filing)₹76.32M
Total Debt (Recent Filing)₹2.24B
Price to Earnings (P/E)14.3
Beta1.88
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.48
Shares Outstanding34,939,400
10 Day Avg. Volume8,584
30 Day Avg. Volume8,255
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.6
Revenue Forecast (FY)₹8.76B
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (Formulations + APIs)Wanbury's dual focus on finished-dose formulations and APIs provides durable revenue diversification. Formulations capture branded/generic domestic demand while APIs supply global manufacturers, reducing single-market dependence and supporting more stable medium-term cash flows and customer reach.
Sustained Revenue Growth TrendThe multi-year revenue recovery and sequential growth since FY2023 indicate improving product traction and market share. A steady top-line expansion supports better capacity utilization and provides a foundation for margin and profit stabilization over the next several quarters.
Balance-sheet Recovery To Positive EquityReverting from prior negative equity to positive equity reduces insolvency risk and improves creditor confidence. This repair enhances access to financing and strategic flexibility, enabling investment in manufacturing or product development over a 2–6 month horizon and beyond.
Bears Say
Weak Cash Generation / Negative FCFReported profits are not translating into cash, raising reliance on external funding for working capital and capex. Persistent negative free cash flow heightens execution and refinancing risk, constraining the company's ability to self-fund growth or reduce leverage over the medium term.
Elevated Leverage (debt > Equity)High leverage increases interest expense sensitivity and refinancing vulnerability, limiting financial flexibility. With debt sizable relative to equity, the company faces higher funding costs and reduced capacity for opportunistic investment or cushioning against industry shocks.
Margin Volatility And CompressionInconsistent margins and recent compression suggest cost or pricing pressures and uneven earnings quality. Margin volatility undermines sustainable profitability and makes forecasting cash generation and capital allocation decisions riskier across the next several quarters.
Wanbury Limited News
WANBURY FAQ
What was Wanbury Limited’s price range in the past 12 months?
Wanbury Limited lowest stock price was ₹162.00 and its highest was ₹360.00 in the past 12 months.
What is Wanbury Limited’s market cap?
Wanbury Limited’s market cap is ₹10.27B.
When is Wanbury Limited’s upcoming earnings report date?
Wanbury Limited’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were Wanbury Limited’s earnings last quarter?
Wanbury Limited released its earnings results on May 29, 2026. The company reported ₹6.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.2.
Is Wanbury Limited overvalued?
According to Wall Street analysts Wanbury Limited’s price is currently Overvalued.
Does Wanbury Limited pay dividends?
Wanbury Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Wanbury Limited dividends here
What is Wanbury Limited’s EPS estimate?
Wanbury Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wanbury Limited have?
Wanbury Limited has 34,939,400 shares outstanding.
What happened to Wanbury Limited’s price movement after its last earnings report?
Wanbury Limited reported an EPS of ₹6.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.31%.
Which hedge fund is a major shareholder of Wanbury Limited?
Currently, no hedge funds are holding shares in IN:WANBURY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wanbury Limited
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulations addresses numerous therapeutic areas, including women's health, bone and joint conditions, hematological disorders, diabetes management, nutritional support, gastrointestinal ailments, post-stroke recovery, infectious diseases, respiratory issues, inflammatory conditions, pain relief, and general medicine, marketed under approximately 70 different brands. Additionally, Wanbury supplies APIs vital for medicines treating diabetes, pain, depression, allergies, inflammation, arthritis, thrombosis, epilepsy, and hypertension. The company extends its reach beyond India through product exports. Originally incorporated in 1988 as Pearl Organics Limited, the firm was rebranded as Wanbury Limited in 2004 and maintains its corporate headquarters in Navi Mumbai, India.
Technical Analysis
Jagsonpal Pharmaceuticals Ltd.
―
Kilitch Drugs (India) Limited
―
Lincoln Pharmaceuticals Ltd
―
Zim Laboratories Ltd.
―
Anuh Pharma Limited
―